Proprotein convertase subtilisin/kexin type 9 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Proprotein convertase subtilisin/kexin type 9 shows approved-linked disease relevance led by Hypercholesterolemia. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q8NBP7. Start with Hypercholesterolemia, then reuse UniProt Q8NBP7 as the stable protein anchor across project notes and exports.
Start with Hypercholesterolemia, then reuse UniProt Q8NBP7 as the stable protein anchor across project notes and exports.
Proprotein convertase subtilisin/kexin type 9 shows approved-linked disease relevance led by Hypercholesterolemia. 5 more disease programs remain visible in the same review block. 8 linked drugs remain visible in the same block.
Start review with Hypercholesterolemia because it currently carries approved-linked support. Linked drugs include ALIROCUMAB, BOCOCIZUMAB, EVOLOCUMAB, FROVOCIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyProprotein convertase subtilisin/kexin type 9
Review this target as Proprotein convertase subtilisin/kexin type 9, mapped to UniProt Q8NBP7. Sequence length is 692 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Proprotein convertase subtilisin/kexin type 9 as ChEMBL target CHEMBL2929, mapped to UniProt Q8NBP7. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Proprotein convertase subtilisin/kexin type 9 is the right protein anchor across sources, using UniProt Q8NBP7 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Hypercholesterolemia is currently framed as approved-linked support. It currently carries 8 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Proprotein convertase subtilisin/kexin type 9 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q8NBP7 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Proprotein convertase subtilisin/kexin type 9 |
| UniProt Accession | Q8NBP7 |
| Component Type | Protein |
| Sequence Length | 692 aa |
Proprotein convertase subtilisin/kexin type 9
Review this target as Proprotein convertase subtilisin/kexin type 9, mapped to UniProt Q8NBP7. Sequence length is 692 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Proprotein convertase subtilisin/kexin type 9 shows approved-linked disease relevance led by Hypercholesterolemia. 5 more disease programs remain visible in the same review block.
Start review with Hypercholesterolemia because it currently carries approved-linked support. Linked drugs include ALIROCUMAB, BOCOCIZUMAB, EVOLOCUMAB, FROVOCIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5084416 | 10.94 | Ki | 0.01136 | Preclinical |
| CHEMBL5082483 | 10.43 | Ki | 0.037 | Preclinical |
| CHEMBL4642977 | 9.82 | IC50 | 0.152 | Preclinical |
| CHEMBL4780905 | 9.82 | EC50 | 0.15 | Preclinical |
| CHEMBL5081587 | 9.8 | Ki | 0.16 | Preclinical |
| CHEMBL5087487 | 9.64 | Ki | 0.23 | Preclinical |
| CHEMBL5086286 | 9.6 | Ki | 0.25 | Preclinical |
| CHEMBL4785006 | 9.55 | EC50 | 0.28 | Preclinical |
| CHEMBL5271747 | 9.52 | Kd | 0.3 | Preclinical |
| CHEMBL4635142 | 9.48 | IC50 | 0.327 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 90 | 118 | 5.6 |
| single protein format | 40 | 193 | 6.4 |
| cell-free format | 3 | 0 | — |
| assay format | 2 | 15 | 5.5 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |